{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T09:58:20Z","timestamp":1794391100932,"version":"4.9.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007542","name":"Agence Fran\u00e7aise de S\u00e9curit\u00e9 Sanitaire des Produits de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.therap.2024.10.055","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:24:49Z","timestamp":1729643089000},"page":"187-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["ASOS, a national monitoring study to assess narcotic prescriptions and indications in France since 2001"],"prefix":"10.1016","volume":"80","author":[{"given":"Joelle","family":"Perri-Pland\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Miremont-Salam\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Perino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gibaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Daveluy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.10.055_bib0005","series-title":"Report 2023","year":"2024"},{"key":"10.1016\/j.therap.2024.10.055_bib0010","series-title":"Convention on psychotropic substances","year":"1971"},{"key":"10.1016\/j.therap.2024.10.055_bib0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2515\/therapie\/2015009","article-title":"Signal identification in addictovigilance: the functioning of the French system","volume":"70","author":"Jouanjus","year":"2015","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.055_bib0020","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.therap.2019.09.005","article-title":"Safety signal detection by the French Addictovigilance Network: innovative methods of investigation, examples and usefulness for public health","volume":"74","author":"Micallef","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.055_bib0025","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000337028","article-title":"Misuse of medicines in the European Union: a systematic review of the literature","volume":"18","author":"Casati","year":"2012","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.therap.2024.10.055_bib0030","doi-asserted-by":"crossref","first-page":"e060519","DOI":"10.1136\/bmjopen-2021-060519","article-title":"Protocol for a scoping review on misuse of psychoactive medicines and its consequences","volume":"12","author":"Araujo","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.therap.2024.10.055_bib0035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.therap.2018.07.007","article-title":"From psychoactive medicines to addictovigilance in French Public Health Code (1990\u20132017)","volume":"74","author":"Baumevieille","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.055_bib0040","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40264-021-01124-5","article-title":"A 13-year national monitoring study to assess narcotic prescriptions and indications (2007\u20132019)","volume":"45","author":"Perri-Plande","year":"2022","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2024.10.055_bib0045","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.therap.2024.10.053","article-title":"From the first pilot initiatives in the early 1990s to the national OSIAP survey in the 2020s: more than 30 years of insight in medication diversion phenomenon in France","volume":"80","author":"Lapeyre-Mestre","year":"2025","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.055_bib0050","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.therap.2024.10.054","article-title":"Monitoring misuse and abuse of psychoactive substances in France: insights from substance abuse treatment facilities through the OPPIDUM program","volume":"80","author":"Lacroix","year":"2025","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.055_bib0055","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.therap.2024.10.059","article-title":"DRAMES and DTA registers: complementary tools for monitoring drug-related deaths in France","volume":"80","author":"Revol","year":"2025","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.055_bib0060","doi-asserted-by":"crossref","first-page":"102297","DOI":"10.1016\/j.legalmed.2023.102297","article-title":"Assessment of 19 years of a prospective national survey on drug-facilitated crimes in France","volume":"65","author":"Djezzar","year":"2023","journal-title":"Leg Med (Tokyo)"},{"key":"10.1016\/j.therap.2024.10.055_bib0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.therap.2024.10.056","article-title":"From regional signal to alert in addictovigilance","volume":"80","author":"Daveluy","year":"2025","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.055_bib0070","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/pds.3369","article-title":"Identification of abuse and dependence cases through a hospital database","volume":"21","author":"Daveluy","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2024.10.055_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.puhe.2023.07.004","article-title":"Increase in hospitalisation-associated methadone intoxication in France following first COVID-19 lockdown","volume":"223","author":"Perino","year":"2023","journal-title":"Public Health"},{"key":"10.1016\/j.therap.2024.10.055_bib0080","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.therap.2024.10.058","article-title":"Inputs of pharmacoepidemiology in addictovigilance: how do they fit together?","volume":"80","author":"Soeiro","year":"2025","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.055_bib0085","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/fcp.12368","article-title":"Tamper-resistant prescription forms for narcotics in France: should we generalize them?","volume":"32","author":"Daveluy","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.055_bib0090","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1472-8206.2009.00678.x","article-title":"Medicines submitted to narcotics regulations in France, 1992\u20132007","volume":"23","author":"Baumevieille","year":"2009","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.055_bib0095","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bcp.13792","article-title":"Prevalence and incidence of prescription opioid analgesic use in Australia","volume":"85","author":"Lalic","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.055_bib0100","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.drugalcdep.2018.01.036","article-title":"Doctor shopping of opioid analgesics relative to benzodiazepines: a pharmacoepidemiological study among 11.7 million inhabitants in the French countries","volume":"187","author":"Ponte","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2024.10.055_bib0105","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1370\/afm.2098","article-title":"Mortality associated with time in and out of buprenorphine treatment in French office-based general practice: a 7-year cohort study","volume":"15","author":"Dupouy","year":"2017","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.therap.2024.10.055_bib0110","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.therap.2019.11.002","article-title":"French trends in the misuse of fentanyl: from 2010 to 2015","volume":"75","author":"Tournebize","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.055_bib0115","series-title":"Misuses and risks of transmucosal fentanyl","year":"2020"},{"key":"10.1016\/j.therap.2024.10.055_bib0120","series-title":"Rapport d\u2019enqu\u00eate d\u2019addictovigilance. Oxycodone, donn\u00e9es 2021\u20132022","author":"Lapeyre-Mestre","year":"2024"},{"key":"10.1016\/j.therap.2024.10.055_bib0125","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bcp.14415","article-title":"Ten-year trend of opioid and non-opioid analgesic use in the French adult population","volume":"87","author":"Daveluy","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.055_bib0130","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1124\/pharmrev.121.000506","article-title":"Oxycodone: a current perspective on its pharmacology, abuse, and pharmacotherapeutic developments","volume":"75","author":"Barrett","year":"2023","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.therap.2024.10.055_bib0135","doi-asserted-by":"crossref","first-page":"1229439","DOI":"10.3389\/fpsyt.2023.1229439","article-title":"Oxycodone, an opioid like the others?","volume":"14","author":"Marie","year":"2023","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2024.10.055_bib0140","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ajem.2014.01.015","article-title":"Prevalence and treatment of pain in EDs in the United States, 2000 to 2010","volume":"32","author":"Chang","year":"2014","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.therap.2024.10.055_bib0145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ije\/7.2.139","article-title":"\u2018The analgesic abuse syndrome\u2019: an epidemiological perspective","volume":"7","author":"Christie","year":"1978","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.therap.2024.10.055_bib0150","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/bcp.13564","article-title":"Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe","volume":"84","author":"Hider-Mlynarz","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.055_bib0155","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1503\/cmaj.090784","article-title":"Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone","volume":"181","author":"Dhalla","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.therap.2024.10.055_bib0160","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1097\/PR9.0000000000000599","article-title":"The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain: a perspective from different continents","volume":"2","author":"Hauser","year":"2017","journal-title":"Pain Rep"},{"key":"10.1016\/j.therap.2024.10.055_bib0165","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/clpt.2010.154","article-title":"Prescription drug abuse: insight into the epidemic","volume":"88","author":"Hernandez","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2024.10.055_bib0170","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1097\/j.pain.0000000000000892","article-title":"Polysubstance use and misuse or abuse of prescription opioid analgesics: a multi-level analysis of international data","volume":"158","author":"Morley","year":"2017","journal-title":"Pain"},{"key":"10.1016\/j.therap.2024.10.055_bib0175","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/cpt.1062","article-title":"The CDC Opioid Guideline: proponent interpretation has led to misinformation","volume":"103","author":"Wegrzyn","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2024.10.055_bib0180","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/fcp.12401","article-title":"Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network?","volume":"32","author":"Gentile","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.055_bib0185","series-title":"Bon usage des m\u00e9dicaments opio\u00efdes\u00a0: antalgie, pr\u00e9vention et prise en charge du trouble de l\u2019usage et des surdoses","year":"2022"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724001719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724001719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:34:06Z","timestamp":1744202046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595724001719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0040595724001719"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.10.055","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ASOS, a national monitoring study to assess narcotic prescriptions and indications in France since 2001","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.10.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}